MYELOMA VIIIth trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN52157196

Enrollment

1000

Registered

2000-10-25

Start date

1993-11-01

Completion date

Unknown

Last updated

2019-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukaemia Cancer Leukaemia

Interventions

All patients receive three courses of ABCM. They are then randomised to continue with ABCM or to change to oral weekly cyclophosphamide.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Greater than 65 years old and less than 75 years old 2. Myeloma 3. No previous cytotoxic therapy 4. Netrophil count greater than or equal to 1.3 x 10^9/l 5. Platelet count greater than or equal to 75 x 10^9/L 6. Able to tolerate 3 l of fluid per day 7. Apyrexial 8. Free from infection 9. Informed consent

Exclusion criteria

Exclusion criteria: Patients with equivocal myelomatosis

Design outcomes

Primary

Measure	Time frame
1. Survival 2. Obtaining plateau (stable disease with no more than minimal symptoms) 3. Quality of life	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026